Pharmaceutical MNCs’ China Growth Surpassed 20 Percent In 2008
This article was originally published in PharmAsia News
Executive Summary
Pharmaceutical MNCs in China delivered good performance in 2008, with growth hitting more than 20 percent. The revenues of GSK, AstraZeneca, Roche and Novartis increased 24 percent, 25 percent, 30 percent and 29 percent, respectively. GSK's prescription drug business jumped 30 percent, while Novartis' revenue hit RMB 2 billion, with six products surpassing RMB 100 million each. Industry insiders observe that although the absolute value of pharmaceutical MNCs' revenue in China only contributes 1 to 2 percent of their global revenues, these companies will all increase investment and expand their workforces in the country. This is due to the positive demand for medical consumption, expanding medical insurance coverage and the small base that makes sustaining high growth easier. (Click here for more - Chinese language)
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.